-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

626.O2.6 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Incorporating novel agents and new adoptive cell therapy approaches

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Biological, therapy sequence, Lymphoma (any), Diseases, Hodgkin Lymphoma, Therapies, Combinations, CAR-Ts, checkpoint inhibitors, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant
Monday, December 7, 2020: 9:00 AM-10:30 AM
Stephen D. Smith, MD, University of Washington and Reem Karmali, MD, MSc, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University
Karmali: Gilead/Kite: Honoraria, Other, Research Funding, Speakers Bureau; BMS/Celgene/Juno: Honoraria, Other, Research Funding, Speakers Bureau; BeiGene: Speakers Bureau; AstraZeneca: Speakers Bureau; Karyopharm: Honoraria; Takeda: Research Funding.
9:00 AM

Eliza A Hawkes, FRACP, MD, MBBS1,2, Geoffrey Chong, MD2,3, Charmaine Smith4*, Sze-Ting Lee5,6,7*, Leonid Churilov8*, Joseph McKendrick9*, William Renwick10, Piers Blombery, MBBS11,12*, Niles Elizabeth Nelson, BSc, MBBS13*, Tineke Fancourt14*, Joanne Hawking15*, Wendi Lin16*, Andrew M Scott5,6,7*, Allison Barraclough16*, Joel Wight16,17,18, Andrew Grigg, MBBS, MD, FRACP, FRCPA16*, Colm Keane, MD19, Chun Yew Fong, MBBS, PhD, FRACP, FRCPA20,21 and Kate Manos, MBBS16,17

1Department of Medical Oncology and Haematology, Eastern Health, Box Hill, Australia
2Austin Health and Olivia Newton John Cancer Research Institute, Heidelberg, Australia
3Ballarat Regional Integrated Cancer Centre, Melbourne, VIC, Australia
4Cancer Clinical Trials Centre, Olivia Newton-John Cancer & Wellness Centre, Heidelberg, Australia
5School of Cancer Medicine, La Trobe University, Melbourne, Australia
6Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia
7Olivia Newton-John Cancer Research Institute, Melbourne, Australia
8Melbourne Brain Centre, Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
9Department of Medical Oncology and Haematology, Eastern Health, Melbourne, Australia
10Department of Haematology, Western Health, Melbourne, Australia
11Department of Pathology, Peter MacCallum Cancer Center, East Melbourne, Australia
12Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
13Peter MacCallum Cancer Centre, Melbourne, Australia
14Department of Anatomical Pathology, Austin Health, Melbourne, VIC, Australia
15Austin Health, Heidelberg, Australia
16Department of Haematology, Austin Health, Melbourne, Australia
17University of Melbourne, Melbourne, Australia
18Townsville University Hospital, Douglas, Australia
19Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
20Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia
21Department of Clinical Haematology, Austin Hospital, Melbourne, VIC, Australia

9:15 AM

Christopher Melani, MD1, Rahul Lakhotia, MD1, Stefania Pittaluga, MD, PhD2, Milos D. Miljkovic, MD, MSc1, James D. Phelan, PhD1*, Jagan R. Muppidi, MD, PhD1*, Craig J. Thomas, PhD3*, Michele Ceribelli, PhD3*, Frances Anne Tosto, MS3*, Craig A. Portell, MD4, Rafic J. Farah, MD5, Seung Tae Lee, MD, PhD6*, Anna Marie Juanitez, RN1*, Seth M. Steinberg, PhD7*, Elaine S. Jaffe, MD2, Mark Roschewski, MD8, Louis M. Staudt, MD, PhD1 and Wyndham H. Wilson, MD, PhD1

1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
3Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD
4Division of Hematology and Oncology, University of Virginia, Charlottesville, VA
5UPMC Hillman Cancer Center, Pittsburgh, PA
6University of Maryland, School of Medicine, Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD
7Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD
8Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

9:30 AM

Giuseppe Gritti, MD, PhD1*, Paula Marlton, MBBS FRACP FRCPA2, Tycel J. Phillips, MD3, Christopher Arthur4, Rajat Bannerji, MD, PhD5, Paolo Corradini6, Anna Johnston7*, John F. Seymour, MBBS8, Sam Yuen, MBBS, FRACP, FRCPA9, Jamie Hirata10, Lisa Musick, PharmD, BCPS11*, Sourish Saha10*, Brandon Croft10* and Christopher Flowers, MD, MS12

1ASST Papa Giovanni XXIII, Bergamo, Italy
2University of Queensland, Brisbane, Australia
3University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
4Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia
5Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
6Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
7Royal Hobart Hospital (RHH), Hobart, Australia
8Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
9Calvary Mater Newcastle, Waratah, Australia
10Genentech, Inc., South San Fransisco, CA
11Genentech, South San Francisco, CA
12The Winship Cancer Institute of Emory University, Atlanta, GA

9:45 AM

Aravind Ramakrishnan, MD1, Kirit M. Ardeshna2, Connie Lee Batlevi, MD, PhD3, Maria A V Marzolini4*, Wendy Osborne, MBBS5*, Eleni Tholouli, MD, MRCPath6*, Carlos Bachier, MD7, Peter A. McSweeney, MD8*, Elizabeth Budde, MD PhD9, Nancy L. Bartlett, MD10*, Yiyun Zhang, PhD11*, Muhammad Al-Hajj, PhD, BSc12, Martin Pule, MD12*, Simon Thomas, PhD12*, Maud Jonnaert, PhD13*, Vijay G R Peddareddigari12*, Nushmia Z Khokhar, MD12, Robert Chen, MD14 and Lazaros J. Lekakis, MD15*

1Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
2Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
3Memorial Sloan Kettering Cancer Center, New York, NY
4UCL Cancer Institute, London, United Kingdom
5Department of Haematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
6Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
7Texas Transplant Institute, Nashville, TN
8Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO
9T Cell Therapeutics Research Laboratory, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
10Washington University School of Medicine Siteman Cancer Center, St. Louis, MO
11Autolus Therapeutics, London, NJ, United Kingdom
12Autolus Ltd, London, United Kingdom
13Autolus Therapeutics, Basel, Switzerland
14Autolus Limited, London, United Kingdom
15Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

10:00 AM

Rui Zhang, MSc1*, Yuhua Li, MD & PhD2, Sanfang Tu, MD & PhD2*, Rui Huang, MD & PhD2*, Xun Lai, MD3, Leping Zhang, MD, PhD4*, Eugene E. Zvonkov, MD, PhD5*, Valeriy G. Savchenko, MD, PhD6, Nelly G Gabeeva, PhD5*, Yuchen Liu, MSc1*, Yuchen Li, MSc1*, Cheng Jiao, MD, PhD1*, Lan Deng, MD, PhD2*, Xuan Zhou, MD2*, Hongyu Zhang, MD, PhD7, Wenli Zhang, MD7* and Lung-Ji Chang, PhD1

1Geno-Immune Medical Institute, Shenzhen, China
2Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
3Department of Hematology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
4Department of Hematology, Peking University People's Hospital, Beijing, China
5National Research Center for Hematology, Moscow, Russian Federation
6National Research Center for Hematology, Moscow, Russian Federation, Moscow, Russian Federation
7Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China

*signifies non-member of ASH